A global collaboration to advance vaccine product innovations – The Vaccine Innovation Prioritisation Strategy

Kristensen, Debra; Giersing, Birgitte; Hickling, Julian; Kazi, Fatima; Scarna, Tiziana; Kahn, Anna-Léa; Hsu, Vivian M.; Gandrup-Marino, Kristoffer; Menozzi-Arnaud, Marion

doi:10.1016/j.vaccine.2021.05.102

Cited by 12 publications

(9 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MAPs are likely to surpass CPADs on several product fronts (size, no sharps waste, ease of use), and due to ongoing catalytic work being undertaken by global stakeholders. Specifically, MAPs were prioritized by the Vaccine Innovation Prioritisation Strategy Alliance, which has developed action plans to accelerate their development for several vaccine applications, is incentivizing investment in MAPs, and is engaging in activities that will position MAPs for greater uptake once available [24,25,31,67]. 2.…”

Section: Discussionmentioning

confidence: 99%

“…This vaccine presentation could assist in overcoming barriers to increasing timely hepatitis B birth dose coverage in LMICs. MAPs eliminate the need for a needle and syringe to deliver a vaccine [24,25]; instead, dry antigen is released from micron-scale projections which only penetrate the outermost layer of skin (stratum corneum) [26], and could facilitate vaccination of newborns by individuals with no or minimal prior training [27]. Acceptability of lay-health workers (such as trained community members) to deliver vaccines to infants has previously been established for CPADs [28], and evidence for MAPs indicates use in this capacity may also be considered acceptable [29][30][31].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluating the potential cost-effectiveness of microarray patches to expand access to hepatitis B birth dose vaccination in low-and middle-income countries: A modelling study

Seaman

Mvundura

Frivold

et al. 2022

PLOS Glob Public Health

View full text Add to dashboard Cite

Timely birth dose vaccination is key for achieving elimination of hepatitis B, however, programmatic requirements for delivering current vaccine presentations to births outside of health facilities inhibits coverage within many low-and middle-income countries (LMICs). Vaccine technologies in development such as microarray patches (MAPs) could assist in overcoming these barriers, but procurement could incur higher per-dose commodity costs than current ten-dose (US$0.34) and single-dose (US$0.62) vial presentations, necessitating an evaluation of the economic value proposition for MAPs. Within 80 LMICs offering universal hepatitis B birth dose vaccination, the cost-effectiveness of using MAPs to expand coverage was evaluated using a mathematical model. We considered three potential per dose MAP prices (US$1.65, US$3.30, and US$5.00), and two potential MAP use-cases: (1) MAPs are used by lay-health workers to expand birth dose coverage outside of health facility settings, and (2) MAPs are also preferred by qualified health workers, replacing a proportion of existing coverage from vaccine vials. Analysis took the health system perspective, was costed in 2020 US$, and discounted at 3% annually. Across minimal (1% additional coverage) and maximal (10% additional and 10% replacement coverage) MAP usage scenarios, between 2.5 (interquartile range [IQR]: 1.9, 3.1) and 38 (IQR: 28,44) thousand DALYs were averted over the estimated 2020 birth cohort lifetime in 80 LMICs. Efficiency of MAPs was greatest when used to provide additional coverage (scenario 1), on average saving US$88.65 ($15.44, $171.22) per DALY averted at a price of US$5.00 per MAP. Efficiency was reduced when used to replace existing coverage (scenario 2); however, at prices up to US$5.00 per MAP, we estimate this use-case could remain cost-effective in at least 73 (91%) modelled LMICs. Our findings suggest even at higher procurement costs, MAPs are likely to represent a highly cost-effective or cost-saving mechanism to expand reach of birth dose vaccination in LMICs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Evaluating the potential cost-effectiveness of microarray patches to expand access to hepatitis B birth dose vaccination in low-and middle-income countries: A modelling study

Seaman

Mvundura

Frivold

et al. 2022

PLOS Glob Public Health

View full text Add to dashboard Cite

show abstract

“…To improve vaccine administration, VIPS has assessed innovative technologies and conducted stakeholder consultations to develop consensus on what new vaccine technologies are needed to increase coverage. VIPS partners are now accelerating the advancement of selected new technologies [39] , [40] , [41] .…”

Section: Lessons From Covid-19mentioning

confidence: 99%

Meeting Summary: Global Vaccine and Immunization Research Forum, 2021

Ford

Hwang²,

et al. 2023

Vaccine

Self Cite

View full text Add to dashboard Cite

“…The work of VIPS in facilitating the assessment of the full value of vaccine-MAPs from the perspective of multiple stakeholders, including country immunization stakeholders and policy makers; vaccine manufacturers; MAP developers; and funders and procurers, as well as of the pull incentives required, could not be more timely or critical ( 30 ).…”

Section: Section 9: Summary Conclusion and Recommendationsmentioning

confidence: 99%

Accelerating the Development of Measles and Rubella Microarray Patches to Eliminate Measles and Rubella: Recent Progress, Remaining Challenges

Hasso-Agopsowicz

Crowcroft

Biellik³

et al. 2022

Front. Public Health

Self Cite

View full text Add to dashboard Cite

Measles and rubella microarray patches (MR-MAPs) are critical in achieving measles and rubella eradication, a goal highly unlikely to meet with current vaccines presentations. With low commercial incentive to MAP developers, limited and uncertain funding, the need for investment in a novel manufacturing facility, and remaining questions about the source of antigen, product demand, and regulatory pathway, MR-MAPs are unlikely to be prequalified by WHO and ready for use before 2033. This article describes the current progress of MR-MAPs, highlights challenges and opportunities pertinent to MR-MAPs manufacturing, regulatory approval, creating demand, and timelines to licensure. It also describes activities that are being undertaken by multiple partners to incentivise investment in and accelerate the development of MR-MAPs.

show abstract

A global collaboration to advance vaccine product innovations – The Vaccine Innovation Prioritisation Strategy

Cited by 12 publications

References 2 publications

Evaluating the potential cost-effectiveness of microarray patches to expand access to hepatitis B birth dose vaccination in low-and middle-income countries: A modelling study

Evaluating the potential cost-effectiveness of microarray patches to expand access to hepatitis B birth dose vaccination in low-and middle-income countries: A modelling study

Meeting Summary: Global Vaccine and Immunization Research Forum, 2021

Accelerating the Development of Measles and Rubella Microarray Patches to Eliminate Measles and Rubella: Recent Progress, Remaining Challenges

Contact Info

Product

Resources

About